Jéssica Barreto Ribeiro Dos Santos1, Alessandra Maciel Almeida2, Francisco de Assis Acurcio2, Haliton Alves de Oliveira Junior1, Adriana Maria Kakehasi3, Augusto Afonso Guerra Junior2, Marion Bennie4, Brian Godman4,5, Juliana Alvares2. 1. Postgraduate Program in Medicines & Pharmaceutical Assistance, College of Pharmacy, Federal University of Minas Gerais, Av. Presidente Antônio Carlos, 6627 Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil. 2. College of Pharmacy, Federal University of Minas Gerais, Av. Presidente Antônio Carlos, 6627 Campus Pampulha, Belo Horizonte, Minas Gerais 31270-901, Brazil. 3. Medicine School, Federal University of Minas Gerais, Av. Prof. Alfredo Balena, 190, Belo Horizonte, Minas Gerais 30130-100, Brazil. 4. Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, UK. 5. Division of Clinical Pharmacology, Karolinska Institute, Stockholm, Sweden.
Abstract
AIM: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. METHODS: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also used. RESULTS: A total of 266 RA patients started treatment with adalimumab or etanercept. Adalimumab was the most widely used bDMARD (70%). In total, 46% achieved remission or low-disease activity at 12 months with no difference in effectiveness between them (p = 0.306). bDMARDs were more effective in patients who had better functionality at treatment onset and had spent longer in education. CONCLUSION: This real-world study demonstrated that adalimumab and etanercept are equal alternatives for RA treatment and both were well tolerated.
AIM: Biological disease-modifying antirheumatic drugs (bDMARDs) are used to treat rheumatoid arthritis (RA) with adalimumab and etanercept the most used bDMARDs in Brazil. This open prospective cohort study evaluated their effectiveness and safety among RA patients in the Brazilian Public Health System given their costs. METHODS: The Clinical Disease Activity Index was primarily used to assess their effectiveness after 6 and 12 months of follow-up. The Health Assessment Questionnaire and EuroQol-5D were also used. RESULTS: A total of 266 RA patients started treatment with adalimumab or etanercept. Adalimumab was the most widely used bDMARD (70%). In total, 46% achieved remission or low-disease activity at 12 months with no difference in effectiveness between them (p = 0.306). bDMARDs were more effective in patients who had better functionality at treatment onset and had spent longer in education. CONCLUSION: This real-world study demonstrated that adalimumab and etanercept are equal alternatives for RA treatment and both were well tolerated.
Authors: J A Karlsson; L E Kristensen; M C Kapetanovic; A Gülfe; T Saxne; P Geborek Journal: Rheumatology (Oxford) Date: 2008-02-27 Impact factor: 7.580
Authors: Geertje M Bartelds; Charlotte L M Krieckaert; Michael T Nurmohamed; Pauline A van Schouwenburg; Willem F Lems; Jos W R Twisk; Ben A C Dijkmans; Lucien Aarden; Gerrit Jan Wolbink Journal: JAMA Date: 2011-04-13 Impact factor: 56.272
Authors: Katrina E Donahue; Gerald Gartlehner; Daniel E Jonas; Linda J Lux; Patricia Thieda; Beth L Jonas; Richard A Hansen; Laura C Morgan; Kathleen N Lohr Journal: Ann Intern Med Date: 2007-11-19 Impact factor: 25.391
Authors: Marina Morgado Garcia; Pamela Santos Azevedo; Andrew Mirelman; Leandro Pinheiro Safatle; Roberto Iunes; Marion Clark Bennie; Brian Godman; Augusto Afonso Guerra Junior Journal: Front Pharmacol Date: 2020-04-14 Impact factor: 5.810
Authors: Michael Ruberson Ribeiro da Silva; Jéssica Barreto Ribeiro Dos Santos; Alessandra Maciel Almeida; Alexander Itria; Adriana Maria Kakehasi; Juliana Alvares Teodoro; Francisco de Assis Acurcio Journal: Future Sci OA Date: 2019-01-18